By Connor Hart
Lantheus Holdings will sell its single photon emission computed tomography, or Spect, business to Illuminated Holdings.
The Bedford, Mass., company said Tuesday it will receive an upfront cash payment for the business, though it didn't disclose the amount. It will additionally receive a convertible note for preferred stock of Shine Technologies, a subsidiary of Illuminated, and additional considerations including potential earnout milestones.
The transaction has been approved by both companies' boards and is expected to close by the end of the year, subject to customary conditions.
Under the deal's terms, Shine will acquire Lantheus' Spect business and related products, as well as the portion of Lantheus' campus in Massachusetts that manufactures the products and the business's related operations in Canada.
Spect is a type of nuclear-imaging test that uses radioactive substances to create three-dimensional images of organs and tissues, showing both their function and structure.
Lantheus said the sale will allow it to focus on growing its commercial portfolio of PET radiodiagnostics and microbubbles, while advancing its pipeline of radiopharmaceuticals.
"This acquisition builds on our longstanding partnership with Lantheus," Shine Chief Executive Greg Piefer said, adding he is confident the Spect business and team will strengthen its platform.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
May 06, 2025 17:45 ET (21:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。